News

Virginia Catalyst Announces Round 13 of Grant Funding! Could you use $200,000 to $800,000 in a Non-Dilutive Grant?

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it is accepting letters of intent (LOI) for Grant Round 13 to fund the development and commercialization of life science projects that address major unmet needs for improving human health and advance Virginia’s economy.

“When you combine world class research with entrepreneurial management and capital, then stir, good things happen,” said Mike Grisham, CEO of Virginia Catalyst. “We are looking for passionate research scientists and entrepreneurial leaders in high-growth life science businesses in Virginia who could use $200,000 to $800,000 in non-dilutive grant funding to further a project that improves human health and advances economic development in the Commonwealth. Our Grant Round 13 is now open, and we strongly encourage interested parties to visit the Virginia Catalyst website and apply.”

Letters of Intent (LOI) must be received by March 1, 2022 at 5:00 PM EST. Projects that meet funding criteria will be invited to submit a full application by April 10, 2022. Applications will be reviewed and scored by an independent review team of scientists, venture capitalists and CEOs of Virginia-based life science companies. The top eight applicant teams will be invited to present their proposal the week of May 16, 2022. Awards will be announced at the end of May 2022. The LOI submission form, along with funding criteria and frequently asked questions, are available on the Virginia Catalyst website (www.virginiacatalyst.org/apply.html).

We encourage all interested applicant teams to view our webinar that was co-hosted by Virginia Catalyst and Virginia Bio. This webinar featured an expert panel, facilitated by Mike Grisham, CEO of Virginia Catalyst, to share what it takes to score highly, get funding and position your company and research university for significant follow-on funding from large corporations, venture capitalists, DARPA, NIH and philanthropic foundations. This webinar can be viewed, and the slides downloaded on the home page of Virginia Catalyst at: https://www.virginiacatalyst.org/

Cumulatively through the first twelve funding rounds, Virginia Catalyst has dedicated a total of $24 million for 49 collaborative projects. Together, these projects have created over 200 new jobs and have attracted an additional $250 million of investment capital from venture capital, private equity, corporations and government agencies including DARPA, NIH and NSF. We are proud to continue supporting research investigators and entrepreneurs in achieving value for Virginia and the nation.”

Read more and apply here.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules